Abstract

The Southwest Oncology Group (SWOG) is one of several National Cancer Institute supported clinical cancer research cooperative groups. A multimodality approach is utilized which includes pathology, surgery, chemotherapy, biological response modifier therapy, and radiation therapy for the aim of improving cancer care. specific objectives are prolongation of life, prolonged disease-free survival, improvement in techniques of early detection and prevention, and the rapid transfer of innovative therapies from the laboratory to the clinic.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA020319-19
Application #
2086821
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-01-01
Project End
1997-12-31
Budget Start
1995-03-16
Budget End
1995-12-31
Support Year
19
Fiscal Year
1995
Total Cost
Indirect Cost

  Institution

Name
Swedish Medical Center, First Hill
Department
Type
DUNS #
City
Seattle
State
WA
Country
United States
Zip Code
98122

  Publications

Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Sala Torra, Olga; Othus, Megan; Williamson, David W et al. (2017) Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients. Biol Blood Marrow Transplant 23:691-696
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Othus, M; Mukherjee, S; Sekeres, M A et al. (2016) Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course. Leukemia 30:1779-80
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7
Lawson, David H; Lee, Sandra; Zhao, Fengmin et al. (2015) Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Compl J Clin Oncol 33:4066-76
Schneider, Bryan P; Li, Lang; Radovich, Milan et al. (2015) Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res 21:5082-5091
Cesano, Alessandra; Willman, Cheryl L; Kopecky, Kenneth J et al. (2015) Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia. PLoS One 10:e0118485
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440

Showing the most recent 10 out of 301 publications